The pharmaceutical sector has changed! Lingkang Pharmaceutical, Yisheng Pharmaceutical, etc

【Pharmaceutical Network Pharmaceutical Stock Market】News on December 21, the pharmaceutical sector changed, from the perspective of individual stocks, Lingkang Pharmaceutical, Yisheng Pharmaceutical, etc.
opened up to the limit, Zhongsheng Pharmaceutical rose more than 8% intraday, Shutai Shen, Hisun Pharmaceutical, Xinhua Pharmaceutical, Tuoxin Pharmaceutical, Haichen Pharmaceutical, etc.
followed suit
.
As of 9:42 on December 21, Lingkang Pharmaceutical rose by 10.
03%, with a quotation of 7.
02 yuan, a turnover of 53.
93 million, and a turnover rate of 1.
08%.

As for the reasons for the change in the stock, the analysis believes that the company is mainly engaged in the research and development, production and sales
of chemical prescription drugs.
The company's main products are cardiovascular and cerebrovascular products (Huperzine A for injection, nicergoline for injection, etc.
).

The company is in a leading position
in the domestic chemical preparation industry in many product segments.
At the same time, the company participated in Hainan Cancer Hospital Chengmei International Medical Center Co.
, Ltd.
, with a shareholding ratio of 25%.

In addition, the company has obtained a total of 109 varieties and a total of 191 drug production approval documents, of which 48 varieties have been listed in the national medical insurance catalogue and 13 varieties have been listed in the national basic drug list
.
As of 9:42 on December 21, Yisheng Pharmaceutical rose nearly 5%, with a quotation of 9.
28 yuan, a turnover of 166 million yuan, and a turnover rate of 7.
52%.

On the news, Yisheng Pharmaceutical replied on the interactive platform on December 10 that the company has more than 20 products
for the treatment of colds, antipyretic, cough and antiviral drugs Xiaoqinglong granules, apricot cough granules, pediatric cold granules, children's hot cough clear capsules, compound aminophenolamine tablets, compound Yinqiao ammonia capsules, etc.
In addition, the company has more than 80 types of ginseng series health food and 5 types of
health food.
In addition, the relevant person in charge of the company recently said that he will make every effort to ensure the supply
of medicines and health foods.
It is understood that the main business of Yisheng Pharmaceutical is the research and development, production and sales of drugs, the main products are Zhenyuan capsules, Xinyue capsules, anti-hemorrhoidal injection, red ginseng drinking tablets, American ginseng drinking tablets, red ginseng wheat winter paste, red ginseng refined plant drinks, Dayang hero food, Yiseng Nio series cosmetics luxury lotus series cosmetics
.
As of 9:42 on December 21, Zhongsheng Pharmaceutical rose by more than 7%, with a quotation of 34.
37 yuan, a turnover of 1.
200 billion yuan, and a turnover rate of 5.
00%.

On the news, Zhongsheng Pharmaceutical said on the interactive platform on December 21 that the clinical research of RAY1216 tablets is the core work of the company, and the company is focusing on promoting the randomized, double-blind, placebo-controlled phase III clinical study
of RAY1216 tablets.
It is worth mentioning that Xinhua Pharmaceutical, which fell on December 20 due to the differentiation of the pharmaceutical sector, rose again today, and as of 9:42 on December 21, the stock rose by 4.
25%, with a quotation of 43.
20 yuan, a turnover of 1.
061 billion, and a turnover rate of 5.
63%.

On the news, Xinhua Pharmaceutical said on the interactive platform on December 21 that the company is actively cooperating with the relevant requirements of the national epidemic prevention policy, working overtime to produce urgently needed drugs in the market and making every effort to ensure market supply
.
Xinhua Pharmaceutical, a manufacturer of domestic ibuprofen APIs, has seen 8 price increases in 10 trading days, with a cumulative increase of 115.
82%
since December 5.
For the reason for the stock's soaring rise, the analysis believes that the market sentiment is "impulsive", and after the policy is liberalized, the national drug rush makes it hitchhike with anti-epidemic drugs such as ibuprofen and ursodeoxycholic acid
.
However, as the market gradually "calms down", whether Xinhua Pharmaceutical can go far and go well depends on the company's business performance
.
According to the third quarter report of 2022, the company achieved a total operating income of 5.
453 billion yuan in the first three quarters, a year-on-year increase of 10.
39%; The net profit was 293 million yuan, a year-on-year increase of 2.
84%.

Disclaimer: Under no circumstances does the information or opinions expressed herein constitute investment advice
to anyone.